Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Boehringer Ingelheim

Status and phase: Completed; Phase 3

Conditions: Colorectal Neoplasms

Treatments: Drug: BSC; Drug: Placebo; Drug: Nintedanib (BIBF 1120)

Study type: Interventional

Funder types: Industry

Identifiers

NCT02149108

2012-000095-42 (EudraCT Number)

1199.52

Details and patient eligibility

About

The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.

Enrollment: 768 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >= 18 years
• Signed informed consent
• Histologically or cytologically confirmed colorectal adenocarcinoma
• Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy
• Eastern Cooperative Oncology Group (ECOG) performance status = 1
• At least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
• Progression on standard therapies or withdrawn from standard treatment due to unacceptable toxicity. Previous standard treatment must include all of the following:
• • fluoropyrimidine
• • oxaliplatin: Patients treated with oxaliplatin in adjuvant setting should have progressed within 6 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease
• • irinotecan
• • bevacizumab or aflibercept
• • cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours
• • The remaining standard available therapy as recommended by investigator is best supportive care (note: previous treatment with regorafenib and TAS 102 are allowed and these agents should be administered before study if available to patient according to local standards)
• • Life expectancy of at least 12 weeks
• • Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Transferase (ALT) = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver metastases. Patients with Gilbert syndrome and bilirubin < 2 X ULN and normal AST/ALT are eligible
• Coagulation parameters: International normalised ratio (INR) < 2 and partial prothrombin Time (PTT) = 2xULN

Exclusion criteria

• Previous treatment with nintedanib
• toxicity attributed to previous anticancer therapy that did not resolve to Common Terminology Criteria for Adverse Events (CTCAE) grade =1
• History of other malignancies in the last 5 years, in particular those that could interfere with interpretation of results.
• Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug,
• Significant cardiovascular diseases
• History of severe haemorrhagic or thromboembolic event in the past 12 months
• Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or similar agents requiring therapeutic INR monitoring
• Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug
• Patient with brain metastases that are symptomatic and/or require therapy.
• Patients of childbearing potential who are sexually active and unwilling to use a highly effective method of contraception
• Pregnancy or breast-feeding.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

768 participants in 2 patient groups, including a placebo group

Nintedanib (BIBF 1120) + BSC

Experimental group

Treatment:

Drug: BSC

Drug: Nintedanib (BIBF 1120)

Drug: BSC

Placebo + BSC

Placebo Comparator group

Treatment:

Drug: BSC

Drug: Placebo

Drug: BSC